These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

196 related articles for article (PubMed ID: 32299902)

  • 1. Myeloid/lymphoid neoplasms with eosinophilia/ basophilia and ETV6-ABL1 fusion: cell-of-origin and response to tyrosine kinase inhibition.
    Yao J; Xu L; Aypar U; Meyerson HJ; Londono D; Gao Q; Baik J; Dietz J; Benayed R; Sigler A; Yabe M; Dogan A; Arcila ME; Roshal M; Zhang Y; Mauro MJ; Xiao W
    Haematologica; 2021 Feb; 106(2):614-618. PubMed ID: 32299902
    [No Abstract]   [Full Text] [Related]  

  • 2. Myeloproliferative disorder with eosinophilia and ETV6-ABL gene rearrangement: efficacy of second-generation tyrosine kinase inhibitors.
    Nand R; Bryke C; Kroft SH; Divgi A; Bredeson C; Atallah E
    Leuk Res; 2009 Aug; 33(8):1144-6. PubMed ID: 19394693
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Myeloproliferative neoplasm with eosinophilia and coexisting BCR::ABL1 and PDGFRB rearrangement: favorable and rapid response to imatinib.
    Yao S; Na L; Liangding H
    Ann Hematol; 2024 Aug; 103(8):3247-3250. PubMed ID: 38888615
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Treatment of the myeloid/lymphoid neoplasm with FGFR1 rearrangement with FGFR1 inhibitor.
    Verstovsek S; Subbiah V; Masarova L; Yin CC; Tang G; Manshouri T; Asatiani E; Daver NG
    Ann Oncol; 2018 Aug; 29(8):1880-1882. PubMed ID: 29767670
    [No Abstract]   [Full Text] [Related]  

  • 5. Myeloproliferative neoplasm with ABL1/ETV6 rearrangement mimics chronic myeloid leukemia and responds to tyrosine kinase inhibitors.
    Xie W; Wang SA; Hu S; Xu J; Medeiros LJ; Tang G
    Cancer Genet; 2018 Dec; 228-229():41-46. PubMed ID: 30553471
    [TBL] [Abstract][Full Text] [Related]  

  • 6. NDEL1-PDGFRB fusion gene in a myeloid malignancy with eosinophilia associated with resistance to tyrosine kinase inhibitors.
    Byrgazov K; Kastner R; Gorna M; Hoermann G; Koenig M; Lucini CB; Ulreich R; Benesch M; Strenger V; Lackner H; Schwinger W; Sovinz P; Haas OA; van den Heuvel-Eibrink M; Niemeyer CM; Hantschel O; Valent P; Superti-Furga G; Urban C; Dworzak MN; Lion T
    Leukemia; 2017 Jan; 31(1):237-240. PubMed ID: 27573554
    [No Abstract]   [Full Text] [Related]  

  • 7. Response to tyrosine kinase inhibitors in myeloid neoplasms associated with PCM1-JAK2, BCR-JAK2 and ETV6-ABL1 fusion genes.
    Schwaab J; Naumann N; Luebke J; Jawhar M; Somervaille TCP; Williams MS; Frewin R; Jost PJ; Lichtenegger FS; La Rosée P; Storch N; Haferlach T; Horny HP; Fabarius A; Haferlach C; Burchert A; Hofmann WK; Cross NCP; Hochhaus A; Reiter A; Metzgeroth G
    Am J Hematol; 2020 Jul; 95(7):824-833. PubMed ID: 32279331
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Durable responses to imatinib in patients with PDGFRB fusion gene-positive and BCR-ABL-negative chronic myeloproliferative disorders.
    David M; Cross NC; Burgstaller S; Chase A; Curtis C; Dang R; Gardembas M; Goldman JM; Grand F; Hughes G; Huguet F; Lavender L; McArthur GA; Mahon FX; Massimini G; Melo J; Rousselot P; Russell-Jones RJ; Seymour JF; Smith G; Stark A; Waghorn K; Nikolova Z; Apperley JF
    Blood; 2007 Jan; 109(1):61-4. PubMed ID: 16960151
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Response to imatinib mesylate in patients with chronic myeloproliferative diseases with rearrangements of the platelet-derived growth factor receptor beta.
    Apperley JF; Gardembas M; Melo JV; Russell-Jones R; Bain BJ; Baxter EJ; Chase A; Chessells JM; Colombat M; Dearden CE; Dimitrijevic S; Mahon FX; Marin D; Nikolova Z; Olavarria E; Silberman S; Schultheis B; Cross NC; Goldman JM
    N Engl J Med; 2002 Aug; 347(7):481-7. PubMed ID: 12181402
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Myeloid neoplasms with eosinophilia.
    Reiter A; Gotlib J
    Blood; 2017 Feb; 129(6):704-714. PubMed ID: 28028030
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Characterization of leukemias with ETV6-ABL1 fusion.
    Zaliova M; Moorman AV; Cazzaniga G; Stanulla M; Harvey RC; Roberts KG; Heatley SL; Loh ML; Konopleva M; Chen IM; Zimmermannova O; Schwab C; Smith O; Mozziconacci MJ; Chabannon C; Kim M; Frederik Falkenburg JH; Norton A; Marshall K; Haas OA; Starkova J; Stuchly J; Hunger SP; White D; Mullighan CG; Willman CL; Stary J; Trka J; Zuna J
    Haematologica; 2016 Sep; 101(9):1082-93. PubMed ID: 27229714
    [TBL] [Abstract][Full Text] [Related]  

  • 12. ETV6::ABL1 positive myeloid/lymphoid neoplasms with eosinophilia and tyrosine kinase gene fusions (MLN-TK) with blast crisis treated with flumatinib mesylate.
    Chen F
    Ann Hematol; 2024 Sep; 103(9):3801-3804. PubMed ID: 38992279
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Comprehensive response criteria for myeloid/lymphoid neoplasms with eosinophilia and tyrosine kinase gene fusions: a proposal from the MLN International Working Group.
    Shomali W; Colucci P; George TI; Kiladjian JJ; Langford C; Patel JL; Reiter A; Vannucchi AM; Gotlib J
    Leukemia; 2023 May; 37(5):981-987. PubMed ID: 37076693
    [No Abstract]   [Full Text] [Related]  

  • 14. The Tel-Abl (ETV6-Abl) tyrosine kinase, product of complex (9;12) translocations in human leukemia, induces distinct myeloproliferative disease in mice.
    Million RP; Aster J; Gilliland DG; Van Etten RA
    Blood; 2002 Jun; 99(12):4568-77. PubMed ID: 12036890
    [TBL] [Abstract][Full Text] [Related]  

  • 15. ETV6-ABL1-positive "chronic myeloid leukemia": clinical and molecular response to tyrosine kinase inhibition.
    Perna F; Abdel-Wahab O; Levine RL; Jhanwar SC; Imada K; Nimer SD
    Haematologica; 2011 Feb; 96(2):342-3. PubMed ID: 21193423
    [No Abstract]   [Full Text] [Related]  

  • 16. Acute leukemias with ETV6/ABL1 (TEL/ABL) fusion: poor prognosis and prenatal origin.
    Zuna J; Zaliova M; Muzikova K; Meyer C; Lizcova L; Zemanova Z; Brezinova J; Votava F; Marschalek R; Stary J; Trka J
    Genes Chromosomes Cancer; 2010 Oct; 49(10):873-84. PubMed ID: 20589932
    [TBL] [Abstract][Full Text] [Related]  

  • 17. T cell phenotype and lack of eosinophilia are not uncommon in extramedullary myeloid/lymphoid neoplasms with ETV6::FLT3 fusion: a case report and review of the literature.
    Schoelinck J; Gervasoni J; Guillermin Y; Beillard E; Pissaloux D; Chassagne-Clement C
    Virchows Arch; 2024 May; 484(5):853-857. PubMed ID: 37985498
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Long-term efficacy and safety of nilotinib therapy after imatinib failure in eosinophilic myeloproliferative neoplasm and ETV6-ABL rearrangement.
    Tiribelli M; Barraco D; Medeot M; Marin L; Ottaviani E; De Marchi F; Damiani D; Fanin R
    Ann Hematol; 2015 Aug; 94(8):1423-4. PubMed ID: 25900790
    [No Abstract]   [Full Text] [Related]  

  • 19. Recurrent CEP85L-PDGFRB fusion in patient with t(5;6) and imatinib-responsive myeloproliferative neoplasm with eosinophilia.
    Winkelmann N; Hidalgo-Curtis C; Waghorn K; Score J; Dickinson H; Jack A; Ali S; Cross NC
    Leuk Lymphoma; 2013 Jul; 54(7):1527-31. PubMed ID: 23186533
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Insights from response to tyrosine kinase inhibitor therapy in a rare myeloproliferative neoplasm with CALR mutation and BCR-ABL1.
    Loghavi S; Pemmaraju N; Kanagal-Shamanna R; Mehrotra M; Medeiros LJ; Luthra R; Lin P; Huh Y; Kantarjian HM; Cortes JE; Verstovsek S; Patel KP
    Blood; 2015 May; 125(21):3360-3. PubMed ID: 25999449
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 10.